A Phase IIb Multicenter, Randomized, Double-blind Study of ALX-0061 Administered Subcutaneously as Monotherapy, in Subjects With Moderate to Severe Rheumatoid Arthritis Who Are Intolerant to Methotrexate or for Whom Continued Methotrexate Treatment is Inappropriate

Trial Profile

A Phase IIb Multicenter, Randomized, Double-blind Study of ALX-0061 Administered Subcutaneously as Monotherapy, in Subjects With Moderate to Severe Rheumatoid Arthritis Who Are Intolerant to Methotrexate or for Whom Continued Methotrexate Treatment is Inappropriate

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Vobarilizumab (Primary) ; Tocilizumab
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Ablynx
  • Most Recent Events

    • 17 Jun 2017 Results assessing the safety and efficacy of Vobarilizumab in patients with moderate to severe rheumatoid arthritis, presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 14 Jun 2017 According to an Ablynx media release, results from this trial will be presented at the European Congress of Rheumatology (EULAR).
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top